Same-day ART initiation as a predictor of loss to follow-up and viral suppression among people living with HIV in sub-Saharan Africa.
Options
BORIS DOI
Date of Publication
January 6, 2023
Publication Type
Article
Division/Institute
Contributor
Ross, Jonathan | |
Brazier, Ellen | |
Fatti, Geoffrey | |
Jaquet, Antoine | |
Tanon, Aristophane | |
Diero, Lameck | |
Castelnuovo, Barbara | |
Yiannoutsos, Constantin T | |
Nash, Denis | |
Anastos, Kathryn M | |
Yotebieng, Marcel |
Series
Clinical infectious diseases
ISSN or ISBN (if monograph)
1537-6591
Publisher
Oxford University Press
Language
English
Publisher DOI
PubMed ID
36097726
Uncontrolled Keywords
Description
BACKGROUND
Treat-All guidelines recommend initiation of antiretroviral therapy (ART) for all people living with HIV (PLHIV) on the day of diagnosis when possible, yet uncertainty exists about the impact of same-day ART initiation on subsequent care engagement. We examined the association of same-day ART initiation with loss to follow-up and viral suppression among patients in 11 sub-Saharan African countries.
METHODS
We included ART-naïve adult PLHIV from sites participating in the International epidemiology Databases to Evaluate AIDS consortium (IeDEA) who enrolled in care after Treat-All implementation and prior to January 2019. We used multivariable Cox regression to estimate the association between same-day ART initiation and loss to follow-up, and Poisson regression to estimate the association between same-day ART initiation and 6-month viral suppression.
RESULTS
Among 29,017 patients from 63 sites, 18,584 (64.0%) initiated ART on the day of enrollment. Same-day ART initiation was less likely among those with advanced HIV disease versus early-stage disease. Loss to follow-up was significantly lower among those initiating ART ≥1 day of enrollment, compared with same-day ART initiators (20.6% vs 27.7%; adjusted hazard ratio 0.66, 95% CI 0.57-0.76). No difference in viral suppression was observed by time to ART initiation (adjusted rate ratio 1.00, 95% CI 0.98-1.02).
CONCLUSIONS
Patients initiating ART on the day of enrollment were more frequently lost to follow-up than those initiating later but were equally likely to be virally suppressed. Our findings support recent WHO recommendations for providing tailored counseling and support to patients who accept an offer of same-day ART.
Treat-All guidelines recommend initiation of antiretroviral therapy (ART) for all people living with HIV (PLHIV) on the day of diagnosis when possible, yet uncertainty exists about the impact of same-day ART initiation on subsequent care engagement. We examined the association of same-day ART initiation with loss to follow-up and viral suppression among patients in 11 sub-Saharan African countries.
METHODS
We included ART-naïve adult PLHIV from sites participating in the International epidemiology Databases to Evaluate AIDS consortium (IeDEA) who enrolled in care after Treat-All implementation and prior to January 2019. We used multivariable Cox regression to estimate the association between same-day ART initiation and loss to follow-up, and Poisson regression to estimate the association between same-day ART initiation and 6-month viral suppression.
RESULTS
Among 29,017 patients from 63 sites, 18,584 (64.0%) initiated ART on the day of enrollment. Same-day ART initiation was less likely among those with advanced HIV disease versus early-stage disease. Loss to follow-up was significantly lower among those initiating ART ≥1 day of enrollment, compared with same-day ART initiators (20.6% vs 27.7%; adjusted hazard ratio 0.66, 95% CI 0.57-0.76). No difference in viral suppression was observed by time to ART initiation (adjusted rate ratio 1.00, 95% CI 0.98-1.02).
CONCLUSIONS
Patients initiating ART on the day of enrollment were more frequently lost to follow-up than those initiating later but were equally likely to be virally suppressed. Our findings support recent WHO recommendations for providing tailored counseling and support to patients who accept an offer of same-day ART.
File(s)
| File | File Type | Format | Size | License | Publisher/Copright statement | Content | |
|---|---|---|---|---|---|---|---|
| ciac759.pdf | text | Adobe PDF | 773.89 KB | publisher | accepted | ||
| Ross_ClinInfectDis_2023.pdf | text | Adobe PDF | 553.92 KB | publisher | published |